CRISPR Compositions and Methods for PCSK9 Gene Targeting
Summary
USPTO granted Scribe Therapeutics Patent US12594349B2 covering CRISPR-based gene repressor systems for targeting PCSK9. The patent includes 24 claims for fusion proteins comprising DNA binding domains and guide RNAs useful in repressing PCSK9 transcription. The patent lists 8 inventors including Jason Fernandes, Sean Higgins, and Sarah Denny.
What changed
The USPTO issued Patent US12594349B2 to Scribe Therapeutics Inc. covering compositions and methods for targeting proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene using CRISPR technology. The patent specifically claims fusion proteins combining DNA binding domains (TALE, zinc finger, or catalytically-dead CRISPR) with guide nucleic acids for transcriptional repression of PCSK9. This represents an expansion of intellectual property in the gene editing space for cardiovascular therapeutic applications.\n\nThis patent grant does not impose immediate compliance obligations on other entities. Competitors and researchers developing PCSK9-targeting gene editing technologies should evaluate freedom to operate considerations. Entities seeking to develop similar systems may need licensing arrangements with Scribe Therapeutics or design-around strategies. The patent is effective immediately in the United States with no regulatory compliance deadlines.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for the targeting of PCSK9
Grant US12594349B2 Kind: B2 Apr 07, 2026
Assignee
Scribe Therapeutics Inc.
Inventors
Jason Fernandes, Sean Higgins, Sarah Denny, Ross White, Emeric Jean Marius Charles, Addison Wright, Benjamin Demaree, Benjamin Oakes
Abstract
Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin/kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.
CPC Classifications
C07K 14/4703 C07K 2319/09 C07K 2319/81 C07K 2319/80 C07K 2319/85 C12N 9/1007 C12N 15/113 C12N 2310/20 C12N 2310/531 C12N 9/22 C12N 15/1137 C12N 15/88 C12N 15/907 A61K 48/005 C12Y 201/01037 C12Y 201/01072 C12Y 201/01113
Filing Date
2023-11-21
Application No.
18516722
Claims
24
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.